Literature DB >> 7592715

Identification and characterization of a hepatoma cell-specific enhancer in the mouse multidrug resistance mdr1b promoter.

R Song1, M Ikeguchi, G Zhou, M T Kuo.   

Abstract

The expression of multidrug resistance/P-glycoprotein genes mdr1b(mdr1) and mdr1a(mdr3) is elevated during hepatocarcinogenesis. To investigate the regulation of mdr1b gene expression, we used transient transfection expression assays of reporter constructs containing various 5'-mdr1b flanking sequences in hepatoma and non-hepatoma cells. We found that nucleotides -233 to -116 preferentially enhanced the expression of reporter gene in mouse hepatoma cell lines in an orientation- and promoter context-independent manner. DNase I footprinting using nuclear extracts prepared from hepatoma and non-hepatoma cells identified four protein binding sites at nucleotides -205 to -186 (site A), -181 to -164 (site B), -153 to -135 (site C), and -128 to -120 (site D). Further analyses revealed that, while site B alone played a major part for the enhancer function, sites A and B combined conferred full enhancer activity. Site-directed mutagenesis results also supported these results. Gel retardation experiments using oligonucleotide competitors revealed that the site B contains a dominant binding protein. This is the first report demonstrating a cell type-specific enhancer in the mdr locus. The role of this enhancer in the activation of mdr1b gene during hepatocarcinogenesis is discussed.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7592715     DOI: 10.1074/jbc.270.43.25468

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  8 in total

1.  Multiple courses of immunotherapy with different immune cell types for patients with hepatocellular carcinoma after microwave ablation.

Authors:  Ming-An Yu; Ping Liang; Xiao-Ling Yu; Zhi-Yu Han; Xue-Juan Dong; Y U Wang; Chao Cheng; Xin Li
Journal:  Exp Ther Med       Date:  2015-08-14       Impact factor: 2.447

Review 2.  Biochemical, genetic, and metabolic adaptations of tumor cells that express the typical multidrug-resistance phenotype. Reversion by new therapies.

Authors:  L G Baggetto
Journal:  J Bioenerg Biomembr       Date:  1997-08       Impact factor: 2.945

3.  Absence or pharmacological blocking of placental P-glycoprotein profoundly increases fetal drug exposure.

Authors:  J W Smit; M T Huisman; O van Tellingen; H R Wiltshire; A H Schinkel
Journal:  J Clin Invest       Date:  1999-11       Impact factor: 14.808

4.  Transcriptional regulation of MDR genes.

Authors:  K W Scotto; D A Egan
Journal:  Cytotechnology       Date:  1998-09       Impact factor: 2.058

5.  Immunotherapy of hepatocellular carcinoma: Unique challenges and clinical opportunities.

Authors:  Angela D Pardee; Lisa H Butterfield
Journal:  Oncoimmunology       Date:  2012-01-01       Impact factor: 8.110

6.  Regulation and expression of multidrug resistance (MDR) transcripts in the intestinal epithelium.

Authors:  M Li; R Hurren; R L Zastawny; V Ling; R N Buick
Journal:  Br J Cancer       Date:  1999-06       Impact factor: 7.640

7.  mRNA levels of related Abcb genes change opposite to each other upon histone deacetylase inhibition in drug-resistant rat hepatoma cells.

Authors:  Adám Sike; Enikő Nagy; Balázs Vedelek; Dávid Pusztai; Péter Szerémy; Anikó Venetianer; Imre M Boros
Journal:  PLoS One       Date:  2014-01-07       Impact factor: 3.240

8.  Alpha fetoprotein DNA prime and adenovirus boost immunization of two hepatocellular cancer patients.

Authors:  Lisa H Butterfield; James S Economou; T Clark Gamblin; David A Geller
Journal:  J Transl Med       Date:  2014-04-05       Impact factor: 5.531

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.